Gocovri FDA Approval History
Last updated by Judith Stewart, BPharm on Feb 4, 2021.
FDA Approved: Yes (First approved August 24, 2017)
Brand name: Gocovri
Generic name: amantadine hydrochloride
Dosage form: Extended-Release Capsules
Previous Name: ADS-5102
Company: Adamas Pharmaceuticals, Inc.
Treatment for: Parkinson's Disease
- for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications
- as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.
Development timeline for Gocovri
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.